Sebia

Sebia

Sebia, the global leader in clinical electrophoresis equipment and reagents, offers both capillary separation and agarose gel technologies. Following the acquisition of Orgentec in 2021 Sebia is expanding its core competencies to include autoimmunity testing. Sebia’s automated capillary electrophoresis portfolio, the CAPILLARYS 3 Family and MINICAP Flex Piercing systems, provide full walkaway capability and workload flexibility on our multi-assay instruments. Adding a tube loader with the CAPILLARYS 3 TERA allows for custom configuration of our MC family for added capacity and work cell productivity. Sebia platforms are driven by PHORESIS Core analysis and networking software.
For autoimmunity, Sebia offers the fully automated, random access Alegria 2 ELISA platform*; coupled with a comprehensive menu of antigen assays & panels utilizing a unique Monotest Strip Technology; allowing serum, plasma, and fecal sample testing in the same run. (* Not available in the US.)

Contract Manufacturing, Alcohol Testing, Anemia Testing, Autoimmune Disease Testing, Cancer Testing, Cardiac Testing, Chemistry Testing, Cholesterol Testing, Coagulation/Hemostasis, COVID, Diabetes Testing, Drug Testing, Electrophoresis, Enzyme Testing, Esoteric Testing, Forensic Testing, Genetic Screening, Glycolated Hemoglobin Testing, HbA1c Testing, Hematology, Hemoglobinopathy Testing, Neonatal and Prenatal Testing, Protein Analysis, Thalassemia Testing, Toxicology, Immunofluorescence, Veterinary Products, Analytical Instruments, Capillary Electrophoresis, Chemiluminescence Systems, Chemistry Systems, ELISA, Immunoassay Systems, Immunology, Pipetters/Dispensers, Endocrinology, Serology, Biochemical Markers, Calibrators, Diabetes Markers, Enzymes, Immunoassay Diag/Reagents/Kits, Reagents, Data Collection, Information Systems, Software Services, Quality Control & Management, Cancer Markers, Cardiac Markers, Tumor Markers